Clinical Research

Psychiatry, neuroradiology researchers find imaging markers of inheritable depression

Children are at heightened risk of major clinical depression when at least one parent has a history of the disorder. New research shows depression markers appearing on structural and functional brain MRI ahead of symptoms in these “familial risk” offspring from infancy through early adulthood.

Brain imaging scans unlock mysteries about depression and resilience

The new findings may contain important implications for neuromodulation therapies to treat depression symptoms.

Impella Heart Pump Abiomed RECOVER IV RCT cardiogenic shock

Impella heart pumps linked to improved high-risk PCI outcomes

Researchers examined data from patients who underwent high-risk PCI with either an Impella heart pump or an intra-aortic balloon pump.

Metformin, the popular type 2 diabetes medication, may be an effective AFib treatment

A team of specialists from Cleveland Clinic reviewed nearly 3,000 medications, writing that a common type 2 diabetes medication offered the most potential as an effective treatment for AFib. 

Thumbnail

Experts blame 'perverse incentives' for scientific fraud in radiology research

Nearly 30% of corresponding authors included in the analysis shared that they had witnessed scientific fraud in their department within the last five years.

Cardiologist says COVID-19 vaccinations ‘must stop’ due to the risk of adverse events—scientists and doctors push back

A well-known cardiologist who once fully supported COVID-19 vaccines is now saying he thinks they have done more harm than good. Online, as one might expect, people on both sides of this particular debate have been quick to respond. 

Thumbnail

Can strength and endurance training help heart failure patients live longer?

Researchers have received a five-year grant worth $30 million to study how a new-look physical rehab program impacts outcomes among older HFpEF patients.

The FDFA has cleared tirzepatide (Mounjaro) from Eli Lilly for the treatment of diabetes.

FDA grants fast track designation to tirzepatide, Eli Lilly’s new type 2 diabetes drug, for treating obesity

Back in May, tirzepatide was approved by the FDA for improving glycemic control among adults with type 2 diabetes.